Cyberonics Announces Update On Hagerty Lawsuit
HOUSTON, Feb. 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the lawsuit filed by former employee Andrew Hagerty in federal district court in Massachusetts was voluntarily dismissed without prejudice by Mr. Hagerty on February 1, 2013. The company has asserted that, under the terms of his employment, Mr. Hagerty's claims are subject to binding arbitration. Mr. Hagerty has the right to re-file the lawsuit or to pursue a resolution through binding arbitration.
About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Contact information
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262
Fax: (281) 218-9332
ir@cyberonics.com
SOURCE Cyberonics, Inc.
RELATED LINKS
http://www.cyberonics.com
More by this Source
Cyberonics Reports Record Quarter And Annual Results And Provides Fiscal 2014 Guidance
Jun 05, 2013, 07:00 ET
Cyberonics Announces Response To Submission For Reconsideration Of Coverage Of VNS Therapy® in Treatment-Resistant Depression
May 28, 2013, 17:30 ET
Cyberonics To Participate In Upcoming Investor Conferences
May 28, 2013, 09:00 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.